Target organ involvement in hypertension: a realistic promise of prevention and reversal

被引:16
作者
Frohlich, ED [1 ]
机构
[1] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA
关键词
D O I
10.1016/S0025-7125(03)00117-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
End points from hypertensive disease, stroke, coronary heart disease, and hypertensive emergencies can be markedly reduced. However, cardiac failure and end-stage renal disease, two exceedingly common end points from long-standing hypertension, remain as major disabilities and causes of death. Present day therapy now can effectively reverse these costly (economically and by human suffering) complications, and recent experimental studies suggest that, when used early enough, these newer pharmacologic agents may even prevent their occurrences and consequences. The very practical lesson from these experiences is that early detection and treatment of hypertension, effective control of arterial pressure, and the suppression of the underlying disease mechanisms markedly reduce the now increasing prevalence of both cardiac and renal failure.
引用
收藏
页码:209 / +
页数:14
相关论文
共 70 条
[1]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[2]   DISPARATE STRUCTURAL EFFECTS ON LEFT-AND-RIGHT-VENTRICLES BY ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS AND CALCIUM-ANTAGONISTS IN ESSENTIAL-HYPERTENSION [J].
ARISTIZABAL, D ;
MESSERLI, FH ;
FROHLICH, ED .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (07) :483-487
[3]   BIOCHEMICAL-COMPONENTS AND MYOCARDIAL PERFORMANCE AFTER REVERSAL OF LEFT-VENTRICULAR HYPERTROPHY IN SPONTANEOUSLY HYPERTENSIVE RATS [J].
ARITA, M ;
HORINAKA, S ;
FROHLICH, ED .
JOURNAL OF HYPERTENSION, 1993, 11 (09) :951-959
[4]  
ARITA M, 1993, J HYPERTENS, V11, pS354
[5]  
Black HR, 1997, ARCH INTERN MED, V157, P2413
[6]  
Bottcher M, 1999, CIRCULATION, V99, P1795
[7]  
BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104
[8]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[9]   Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease [J].
Brilla, CG ;
Funck, RC ;
Rupp, H .
CIRCULATION, 2000, 102 (12) :1388-1393
[10]   ANGINA DUE TO CORONARY MICROVASCULAR DISEASE IN HYPERTENSIVE PATIENTS WITHOUT LEFT-VENTRICULAR HYPERTROPHY [J].
BRUSH, JE ;
CANNON, RO ;
SCHENKE, WH ;
BONOW, RO ;
LEON, MB ;
MARON, BJ ;
EPSTEIN, SE .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (20) :1302-1307